JESSICA COOLEY: Open Payments
NPI 1720482441 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,181 in 77 payments from 16 companies in 2025. Trend: 2023 $1,212 · 2024 $1,293 · 2025 $1,181
Food & beverage: $1,181
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $205 |
| PFIZER INC. | 11 | $166 |
| Amgen Inc. | 24 | $137 |
| Novartis Pharmaceuticals Corporation | 4 | $102 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $75 |
| ABBVIE INC. | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| GlaxoSmithKline, LLC. | 3 | $63 |
| Merck Sharp & Dohme LLC | 3 | $62 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
Products named: Veozah, OTEZLA, ELIQUIS, LEQVIO, XIFAXAN, REXULTI, TRELEGY ELLIPTA, ROTATEQ.
Industry payments across AZ — which companies pay providers there.
